A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

June 10, 2022

Conditions
Inguinal Herniorrhaphy
Interventions
DRUG

CPL-01

Subjects will receive a single dose

DRUG

Naropin 150 MG Per 20 ML Injection

Subjects will receive a single dose

DRUG

Placebo

Subjects will receive a single dose

Trial Locations (5)

35660

Shoals Medical Trials, Inc, Sheffield

77401

First Surgical Hospital, Bellaire

84107

Jean Brown Research, Salt Lake City

85053

Arizona Research Center, Phoenix

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Cali Pharmaceuticals LLC

INDUSTRY